Tocilizumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Tocilizumab: From Rheumatoid Arthritis to Ankylosing Spondylitis
One-Sentence Summary
Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody, generally known for its established use in rheumatoid arthritis (RA) and related inflammatory arthritides. The TxGNN model predicts it may also be effective for Ankylosing Spondylitis (AS), with 8 clinical trials and 19 publications currently associated with this direction — though, as detailed below, the two most directly relevant Phase 3 trials in AS were terminated early.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the regulatory dataset (no EU/TW license records found); based on general drug knowledge, tocilizumab’s established indication is Rheumatoid Arthritis (RA) |
| Predicted New Indication | Ankylosing Spondylitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| EU Market Status | Not marketed (per this Evidence Pack) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack (data gap DG002). Based on general pharmacological knowledge, tocilizumab is a humanized monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), and its efficacy in rheumatoid arthritis has been well established through multiple approvals worldwide. Mechanistically, IL-6 is a pleiotropic pro-inflammatory cytokine implicated in the broader systemic inflammatory cascade seen across rheumatic diseases, which provides an initial rationale for testing IL-6 blockade in other inflammatory arthritides.
Rheumatoid arthritis and ankylosing spondylitis are both chronic inflammatory rheumatic conditions that share overlapping biologic treatment classes — most notably TNF inhibitors — and both have historically been considered for IL-6 pathway blockade given shared downstream inflammatory signaling. This shared therapeutic class background is the primary basis for the TxGNN association between tocilizumab and AS.
However, the mechanistic plausibility does not appear to have translated into confirmed clinical benefit. The two Phase 3 RCTs designed specifically to test tocilizumab in AS (NCT01209689 and NCT01209702, the BUILDER-1/BUILDER-2 program) were both terminated early, and the published results (PMID 23765873) describe only short-term symptomatic assessment rather than a positive pivotal outcome. This is consistent with the broader understanding that axial spondyloarthritis pathogenesis is more strongly driven by TNF-α and IL-17 pathways than by IL-6, unlike RA. This tempers confidence in the TxGNN prediction despite its high score.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01209689 | Phase 3 | Terminated | 113 | Randomized, double-blind, placebo-controlled trial of tocilizumab (4 or 8 mg/kg IV) in AS patients with inadequate response to prior TNF antagonist therapy; study was terminated |
| NCT01209702 | Phase 2/3 | Terminated | 306 | Seamless placebo-controlled trial of tocilizumab in TNF-antagonist-naïve AS patients who failed NSAIDs, assessing reduction in signs/symptoms and inhibition of structural damage; study was terminated |
| NCT01965132 | N/A | Recruiting | 10,000 | Korean nationwide registry of biologics and targeted synthetic DMARDs, tracking real-world safety in RA, AS, and PsA patients |
| NCT02569736 | N/A | Completed | 60 | Mechanistic study of tocilizumab’s effect on T follicular helper cells and B cell maturation in RA patients |
| NCT05670301 | N/A | Recruiting | 2,500 | Prospective multi-centre study profiling cytokine biomarkers across systemic inflammatory diseases (not tocilizumab-specific) |
| NCT05696106 | N/A | Unknown | 750,000 | Population-level study of risk of developing additional immune-mediated inflammatory diseases in patients on biologics/immunosuppressants for a single IMID |
| NCT02925338 | N/A | Completed | 1,431 | National real-world observational study of infliximab biosimilar (Inflectra) use; included as a related inflammatory-arthritis biologics registry, not tocilizumab-specific |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Evaluates perioperative immunosuppressant management (including biologics) in rheumatology patients undergoing shoulder arthroplasty |
Note: Both trials designed specifically to test tocilizumab efficacy in AS (NCT01209689, NCT01209702) were terminated prior to completion, which is a significant caution flag for this indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23765873 | 2014 | RCT | Annals of the Rheumatic Diseases | BUILDER-1/BUILDER-2 randomized, placebo-controlled trials assessing short-term symptomatic efficacy of tocilizumab in AS |
| 26986130 | 2016 | Systematic Review/Network Meta-analysis | Medicine | Comparative effectiveness of biologic therapy regimens (including IL-6 blockade) for AS |
| 22452603 | 2012 | Review | Inflammation & Allergy Drug Targets | Short review specifically on antagonizing IL-6 in ankylosing spondylitis |
| 28413099 | 2017 | Review | Seminars in Arthritis and Rheumatism | Second-line biologic therapy optimization in RA, PsA, and AS |
| 20959960 | 2011 | Review | Osteoporosis International | Systemic bone effects of biologic therapies (including IL-6 blockers) in RA and AS |
| 39963138 | 2025 | Review | Frontiers in Immunology | Management of tuberculosis risk with biotechnological/targeted immunosuppressive agents in chronic autoimmune arthritis including AS |
| 29290076 | 2018 | Meta-analysis | Clinical Rheumatology | Risk of serious infections with biologic treatment in AS and non-radiographic axial spondyloarthritis |
| 20851032 | 2010 | Case report | Joint Bone Spine | Tocilizumab used in a patient with AS and Crohn’s disease refractory to TNF antagonists |
| 33981717 | 2021 | Case report/Review | Frontiers in Medicine | Successful treatment of AA amyloidosis in AS using tocilizumab: two cases and literature review |
| 32872025 | 2020 | Case report | Medicine | Ankylosing spondylitis complicating Turner syndrome: two case reports and literature review |
EU Market Information
Currently, no EU/TW marketing authorization is recorded for this drug in the Evidence Pack (market status: not marketed; total authorizations: 0). This should be independently verified, since tocilizumab is a globally recognized biologic and the absence of licensing data here may reflect a data gap in the regulatory source rather than actual market absence.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the TxGNN prediction score is very high (99.99%) and there is a plausible mechanistic rationale (IL-6 blockade in inflammatory rheumatic disease), the two Phase 3 RCTs designed specifically to evaluate tocilizumab in ankylosing spondylitis (NCT01209689, NCT01209702) were both terminated early, suggesting the clinical efficacy signal did not support continued development for this indication. Combined with the Blocking-level data gap on TFDA/EMA safety labeling (DG001) and the missing MOA/original indication data (DG002), the evidence base is currently insufficient to proceed.
To proceed, the following is needed:
- TFDA/EMA SmPC data (warnings, contraindications) to complete the S1 safety pre-assessment — currently a Blocking data gap (DG001)
- Confirmed mechanism of action and original approved indication from DrugBank or regulatory sources (DG002)
- Detailed review of the termination reasons and full results for NCT01209689 and NCT01209702 to determine whether discontinuation reflected a negative efficacy signal or administrative/sponsor decisions unrelated to efficacy
- Verification of tocilizumab’s actual current EU/TW marketing and licensing status, since the “not marketed” flag in this dataset should be cross-checked against known regulatory records
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.